Brief: Tiziana Life Sciences Plans To Submit Ind For Phase 1 Trial Of Intranasal Foralumab In Alzheimer's Disease Patients
12/10/2022 12:06
Oct 12 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES PLANS TO SUBMIT IND FOR PHASE 1
TRIAL OF
INTRANASAL FORALUMAB IN ALZHEIMER'S DISEASE PATIENTS
* PLANS ON FILING IND FOR ALZHEIMER'S DISEASE BY Q3 OF 2023,
THEN
STARTING ITS PHASE 1 PROGRAM BY END OF 2023
Source text for Eikon: ID:nGNX2KGkTq
Further company coverage: TLSA.O
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study